- Home
- HTH vs IOVA Comparison
HTH vs IOVA Comparison
Compare HTH & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | IOVA |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2003 | 2008 |
Fundamental Metrics
Financial Performance| Metric | HTH | IOVA |
|---|---|---|
| Price | $39.23 | $4.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $37.50 | $9.00 |
| AVG Volume (30 Days) | 276.7K | ★ 12.9M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 51.72 | 14.84 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | $3.22 | $40.31 |
| P/E Ratio | $60.44 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $29.20 | $1.67 |
| 52 Week High | $40.41 | $5.63 |
Technical Indicators
Market Signals| Indicator | HTH | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.57 | 57.43 |
| Support Level | $36.20 | $2.07 |
| Resistance Level | $40.41 | $4.35 |
| Average True Range (ATR) | 0.80 | 0.37 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 99.81 | 56.21 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.